OpenMed AI has updated its platform. This update includes a redesigned interface.
Key points
• OpenMed AI has unveiled a new platform interface.
• The update focuses on the platform's visual presentation.
Sources
- OpenMed AI - Official X account for OpenMed AI.
AI for Literature Review - Responsible Use in SciSpace
This content covers how AI tools can accelerate literature review processes. It also emphasizes the importance of responsible AI practices to maintain review quality.
Key points
• AI tools can shorten literature review times from weeks to days.
• Review quality and scrutiny remain paramount despite increased speed.
• A demonstration shows AI-assisted literature review in SciSpace.
• Responsible AI use practices are integrated into the review process.
Sources
- SciSpace - Official X account for SciSpace.
Oncology - I-SPY2 Trial Update on Breast Cancer Treatment
An I-SPY2 trial update indicates a new therapeutic combination for early-stage breast cancer. This treatment strategy involves combining immunotherapy drugs with neoadjuvant paclitaxel.
Key points
• The I-SPY2 trial investigated a combination therapy for early breast cancer.
• Cemiplimab (PD-1) and fianlimab (LAG3) were combined with neoadjuvant paclitaxel.
• This combination improved pCR (pathologic complete response) rates.
• Improvements were observed in triple-negative and hormone receptor-positive (HR+) cases.
Sources
- JAMA Oncology - I-SPY2 trial results on breast cancer treatment.
- KolPulseAI - Official X account for KolPulseAI.
- Stephen V Liu - Official X account for Stephen V Liu.
- Claudine Isaacs - Official X account for Claudine Isaacs.
Oncology - INDIBLADE Trial for Bladder Preservation in MIBC
The INDIBLADE trial, a phase 2 study, explored a bladder preservation strategy for muscle-invasive bladder cancer (MIBC). It combined induction immunotherapy with chemoradiotherapy.
Key points
• The INDIBLADE trial is a phase 2, single-arm, multicenter study.
• It investigates a bladder preservation strategy for MIBC.
• Induction ipilimumab and nivolumab were followed by chemoradiotherapy.
• The study reported long-term bladder-intact outcomes in specific patients.
Sources
- KolPulseAI - Official X account for KolPulseAI.
- Niklas Klümper - Official X account for Niklas Klümper.
AI in Drug Discovery - Insilico DDD Benchmark
The Insilico Drug Discovery Development (DDD) Benchmark provides a platform for evaluating foundation models in drug discovery. It offers standardized evaluation against proprietary data.
Key points
• The Insilico DDD Benchmark assesses AI foundation models for drug discovery.
• Models are evaluated on clean data and can earn a spot on a leaderboard.
• Two evaluation suites are available: Huge Drug Discovery Foundations and Drug Candidate Essentials.
• Baselines are derived from proprietary data from programs reaching preclinical stages.
• Any model accessible via a chat-completions API can be scored.
Implementation
- Submit a model for evaluation on the Insilico DDD Benchmark.
- Choose between a private report or public leaderboard publication.
Sources
- Insilico Medicine - Official X account for Insilico Medicine.
Mental Wellness - Daily Reflection Prompt
This content presents a daily prompt designed for personal reflection and mental check-ins. It encourages users to consider their current state and observations.
Key points
• The prompt encourages self-reflection as a mental wellness practice.
• It asks users to describe their current state and identify existing elements.
• This supports daily journaling and mindfulness.
Sources
- Stoic App - Official X account for the Stoic app.
Precigenetics - LUMA Chip and Software Suite
Precigenetics offers a hardware component paired with a software suite. The software component of this offering is named LUMA.
Key points
• Precigenetics provides a specialized chip.
• The chip is accompanied by a software suite.
• The software suite is identified as LUMA.
Sources
- Precigenetics - Official X account for Precigenetics.